REG - Roquefort Theraptcs. - Update on Acquisition of Oncogeni and Placing

Roquefort TherapeuticsAnnouncement

23/06/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220623:nRSW8587Pa&default-theme=true

RNS Number : 8587P  Roquefort Therapeutics PLC  23 June 2022

23 June 2022

 

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Update on Acquisition of Oncogeni Limited and Placing

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, is pleased
to announce that it has published a corporate presentation with respect to the
proposed acquisition of Oncogeni Limited and the proposed Placing, as
announced by the Company on 22 June 2022.  A copy of the presentation is
available on the Company's website at
https://www.roquefortplc.com/category/presentations/
(https://www.roquefortplc.com/category/presentations/)

 

The Company looks forward to providing further updates in relation to the
acquisition of Oncogeni Limited and the Placing as and when appropriate.

 
Enquiries:

 

 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

 

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma. The Company is a pre-clinical biotech company focused
on developing first in class Midkine targeting drugs for the treatment of
cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQELLFLLQLZBBX